User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

Primary tabs

Hicks, Rodney J Kwekkeboom, Dik J Krenning, Eric Bodei, Lisa Grozinsky-Glasberg, Simona Borbath, Ivan [UCL] Antibes Consensus Conference participants

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish 177Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.

Document type Article de périodique (Journal article) – Article de recherche
Publication date 2017
Language Anglais
Journal information "Neuroendocrinology : international journal for basic and clinical studies on neuroendocrine relationships" - Vol. 105, p. 295-309 (2017)
Peer reviewed yes
Publisher S.Karger AG ((Switzerland) Basel)
issn 0028-3835
e-issn 1423-0194
Publication status Publié
Affiliations UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service d'hépato-gastro-entérologie
Keywords Radiolabelled somatostatin analogues ; Gastroenteropancreatic neuroendocrine tumour ; Neuroendocrine tumour ; Peptide receptor radionuclide therapy
Links
  1. Yao James C., Shah Manisha H., Ito Tetsuhide, Bohas Catherine Lombard, Wolin Edward M., Van Cutsem Eric, Hobday Timothy J., Okusaka Takuji, Capdevila Jaume, de Vries Elisabeth G.E., Tomassetti Paola, Pavel Marianne E., Hoosen Sakina, Haas Tomas, Lincy Jeremie, Lebwohl David, Öberg Kjell, Everolimus for Advanced Pancreatic Neuroendocrine Tumors, 10.1056/nejmoa1009290
  2. Raymond Eric, Dahan Laetitia, Raoul Jean-Luc, Bang Yung-Jue, Borbath Ivan, Lombard-Bohas Catherine, Valle Juan, Metrakos Peter, Smith Denis, Vinik Aaron, Chen Jen-Shi, Hörsch Dieter, Hammel Pascal, Wiedenmann Bertram, Van Cutsem Eric, Patyna Shem, Lu Dongrui Ray, Blanckmeister Carolyn, Chao Richard, Ruszniewski Philippe, Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, 10.1056/nejmoa1003825
  3. Pavel M., O''Toole D., Costa F., Capdevila J., Gross D., Kianmanesh R., Krenning E., Knigge U., Salazar R., Pape U.-F., Öberg K., , ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site, 10.1159/000443167
  4. KRENNING E. P., KOOIJ P. P. M., BAKKER W. H., BREEMAN W. A. P., POSTEMA P. T. E., KWEKKEBOOM D. J., OEI H. Y., JONG M., VISSER T. J., REIJS A. E. M., LAMBERTS S. W. J., Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In-DTPA-d-Phe1]-Octreotide. : A Case History, 10.1111/j.1749-6632.1994.tb17300.x
  5. Krenning E.P., Kooij P.P.M., Pauwels S., Breeman W.A.P., Postema P.T.E., DeHerder W.W., Valkema R., Kwekkeboom D.J., Somatostatin Receptor: Scintigraphy and Radionuclide Therapy, 10.1159/000201398
  6. Valkema Roelf, de Jong Marion, Bakker Willem H., Breeman Wout A.P., Kooij Peter P.M., Lugtenburg Pieternella J., de Jong Frank H., Christiansen Arjan, Kam Boen L.R., de Herder Wouter W., Stridsberg Mats, Lindemans Jan, Ensing Geert, Krenning Eric P., Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience, 10.1053/snuc/2002.31025
  7. Anthony Lowell B., Woltering Eugene A., Espenan Gregory D., Cronin Michele D., Maloney Tom J., McCarthy Kevin E., Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies, 10.1053/snuc.2002.31769
  8. Kong Grace, Johnston Val, Ramdave Shakher, Lau Eddie, Rischin Danny, Hicks Rodney J., High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience, 10.1089/cbr.2009.0644
  9. Otte A., Herrmann R., Heppeler A., Behe M., Jermann E., Powell P., Maecke H. R., Muller J., Yttrium-90 DOTATOC: first clinical results, 10.1007/s002590050476
  10. Waldherr C., Pless M., Maecke H. R., Haldemann A., Mueller-Brand J., The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study, 10.1023/a:1011160913619
  11. Chinol Marco, Bodei Lisa, Cremonesi Marta, Paganelli Giovanni, Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology group, 10.1053/snuc.2002.31563
  12. Paganelli G., Bodei L., Handkiewicz Junak D., Rocca P., Papi S., Lopera Sierra M., Gatti M., Chinol M., Bartolomei M., Fiorenza M., Grana C., 90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies, 10.1002/bip.10349
  13. Bodei Lisa, Cremonesi Marta, Zoboli Stefania, Grana Chiara, Bartolomei Mirco, Rocca Paola, Caracciolo Maurizio, Mäcke Helmut R., Chinol Marco, Paganelli Giovanni, Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study, 10.1007/s00259-002-1023-y
  14. Bushnell David L., O'Dorisio Thomas M., O'Dorisio M. Sue, Menda Yusuf, Hicks Rodney J., Van Cutsem Eric, Baulieu Jean-Louis, Borson-Chazot Francoise, Anthony Lowell, Benson Al B., Oberg Kjell, Grossman Ashley B., Connolly Mary, Bouterfa Hakim, Li Yong, Kacena Katherine A., LaFrance Norman, Pauwels Stanislas A., 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide, 10.1200/jco.2009.22.8585
  15. Imhof Anna, Brunner Philippe, Marincek Nicolas, Briel Matthias, Schindler Christian, Rasch Helmut, Mäcke Helmut R., Rochlitz Christoph, Müller-Brand Jan, Walter Martin A., Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers, 10.1200/jco.2010.33.7873
  16. Baum Richard P., Kluge Andreas W., Kulkarni Harshad, Schorr-Neufing Ulrike, Niepsch Karin, Bitterlich Norman, van Echteld Cees J.A., [177Lu-DOTA]0-D-Phe1-Tyr3-Octreotide (177Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study, 10.7150/thno.13702
  17. Reubi Jean Claude, Schär Jean-Claude, Waser Beatrice, Wenger Sandra, Heppeler Axel, Schmitt Jörg S., Mäcke Helmut R., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use, 10.1007/s002590050034
  18. Kwekkeboom Dik J., Bakker Willem H., Kooij Peter P., Konijnenberg Mark W., Srinivasan Ananth, Erion Jack L., Schmidt Michelle A., Bugaj Joe L., de Jong Marion, Krenning Eric P., [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients, 10.1007/s002590100574
  19. Esser J. P., Krenning E. P., Teunissen J. J. M., Kooij P. P. M., van Gameren A. L. H., Bakker W. H., Kwekkeboom D. J., Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?, 10.1007/s00259-006-0172-9
  20. Kwekkeboom Dik J., de Herder Wouter W., Kam Boen L., van Eijck Casper H., van Essen Martijn, Kooij Peter P., Feelders Richard A., van Aken Maarten O., Krenning Eric P., Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival, 10.1200/jco.2007.15.2553
  21. de Keizer Bart, van Aken Maarten O., Feelders Richard A., de Herder Wouter W., Kam Boen L. R., van Essen Martijn, Krenning Eric P., Kwekkeboom Dik J., Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate, 10.1007/s00259-007-0691-z
  22. Bodei Lisa, Kidd Mark, Paganelli Giovanni, Grana Chiara M., Drozdov Ignat, Cremonesi Marta, Lepensky Christopher, Kwekkeboom Dik J., Baum Richard P., Krenning Eric P., Modlin Irvin M., Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors, 10.1007/s00259-014-2893-5
  23. Kashyap Raghava, Jackson Price, Hofman Michael S., Eu Peter, Beauregard Jean-Mathieu, Zannino Diana, Hicks Rodney J., Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion, 10.1007/s00259-013-2504-x
  24. Sabet Amir, Ezziddin Khaled, Pape Ulrich-Frank, Reichman Karl, Haslerud Torjan, Ahmadzadehfar Hojjat, Biersack Hans-Jürgen, Nagarajah James, Ezziddin Samer, Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate, 10.1007/s00259-013-2601-x
  25. Teunissen Jaap J. M., Krenning Eric P., de Jong Frank H., de Rijke Yolanda B., Feelders Richard A., van Aken Maarten O., de Herder Wouter W., Kwekkeboom Dik J., Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function, 10.1007/s00259-009-1151-8
  26. Khan S., Krenning E. P., van Essen M., Kam B. L., Teunissen J. J., Kwekkeboom D. J., Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate, 10.2967/jnumed.111.087932
  27. Hörsch Dieter, Ezziddin Samer, Haug Alexander, Gratz Klaus Friedrich, Dunkelmann Simone, Miederer Matthias, Schreckenberger Mathias, Krause Bernd Joachim, Bengel Frank M., Bartenstein Peter, Biersack Hans-Jürgen, Pöpperl Gabriele, Baum R.P., Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up, 10.1016/j.ejca.2016.01.009
  28. Zaknun John J., Bodei L., Mueller-Brand J., Pavel M. E., Baum R. P., Hörsch D., O’Dorisio M. S., O’Dorisiol T. M., Howe J. R., Cremonesi M., Kwekkeboom D. J., The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, 10.1007/s00259-012-2330-6
  29. Ezziddin Samer, Khalaf Feras, Vanezi Maria, Haslerud Torjan, Mayer Karin, Al Zreiqat Abdullah, Willinek Winfried, Biersack Hans-Jürgen, Sabet Amir, Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours, 10.1007/s00259-013-2677-3
  30. Sabet Amir, Dautzenberg Kristina, Haslerud Torjan, Aouf Anas, Sabet Amin, Simon Birgit, Mayer Karin, Biersack Hans-Jürgen, Ezziddin Samer, Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine, 10.1007/s00259-015-3041-6
  31. Sansovini Maddalena, Severi Stefano, Ambrosetti Alice, Monti Manuela, Nanni Oriana, Sarnelli Anna, Bodei Lisa, Garaboldi Lucia, Bartolomei Mirco, Paganelli Giovanni, Treatment with the Radiolabelled Somatostatin Analog177Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors, 10.1159/000348394
  32. Barber T.W., Hofman M.S., Thomson B.N.J., Hicks R.J., The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable, 10.1016/j.ejso.2011.08.129
  33. van Vliet E. I., van Eijck C. H., de Krijger R. R., Nieveen van Dijkum E. J., Teunissen J. J., Kam B. L., de Herder W. W., Feelders R. A., Bonsing B. A., Brabander T., Krenning E. P., Kwekkeboom D. J., Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate, 10.2967/jnumed.115.158899
  34. Strosberg Jonathan, El-Haddad Ghassan, Wolin Edward, Hendifar Andrew, Yao James, Chasen Beth, Mittra Erik, Kunz Pamela L., Kulke Matthew H., Jacene Heather, Bushnell David, O’Dorisio Thomas M., Baum Richard P., Kulkarni Harshad R., Caplin Martyn, Lebtahi Rachida, Hobday Timothy, Delpassand Ebrahim, Van Cutsem Eric, Benson Al, Srirajaskanthan Rajaventhan, Pavel Marianne, Mora Jaime, Berlin Jordan, Grande Enrique, Reed Nicholas, Seregni Ettore, Öberg Kjell, Lopera Sierra Maribel, Santoro Paola, Thevenet Thomas, Erion Jack L., Ruszniewski Philippe, Kwekkeboom Dik, Krenning Eric, Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors, 10.1056/nejmoa1607427
  35. Villard Linda, Romer Anna, Marincek Nicolas, Brunner Philippe, Koller Michael T., Schindler Christian, Ng Quinn K.T., Mäcke Helmut R., Müller-Brand Jan, Rochlitz Christoph, Briel Matthias, Walter Martin A., Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers, 10.1200/jco.2011.37.2151
  36. McStay Mary K. G., Maudgil Dave, Williams Martin, Tibballs Jonathan M., Watkinson Anthony F., Caplin Martyn E., Buscombe John R., Large-Volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial90Y-DOTA-Lanreotide as Effective Palliative Therapy, 10.1148/radiol.2372041203
  37. Pool Stefan E., Kam Boen L.R., Koning Gerben A., Konijnenberg Mark, ten Hagen Timo L.M., Breeman Woulter A.P., Krenning Eric P., de Jong Marion, van Eijck Casper H.J., [111In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy, 10.1089/cbr.2013.1552
  38. Hofman Michael S., Hicks Rodney J., Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?, 10.1007/s00259-013-2621-6
  39. van Essen Martijn, Krenning Eric P., Kam Boen L., de Herder Wouter W., van Aken Maarten O., Kwekkeboom Dik J., Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours, 10.1007/s00259-007-0688-7
  40. Hubble Daniel, Kong Grace, Michael Michael, Johnson Val, Ramdave Shakher, Hicks Rodney John, 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide, 10.1007/s00259-010-1483-4
  41. Claringbold Phillip G., Brayshaw Paul A., Price Richard A., Turner J. Harvey, Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours, 10.1007/s00259-010-1631-x
  42. Kong G., Thompson M., Collins M., Herschtal A., Hofman M. S., Johnston V., Eu P., Michael M., Hicks Rodney J., Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT), 10.1007/s00259-014-2788-5
  43. Kashyap Raghava, Hofman Michael S., Michael Michael, Kong Grace, Akhurst Timothy, Eu Peter, Zannino Diana, Hicks Rodney J., Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours, 10.1007/s00259-014-2906-4
  44. Claringbold Phillip G., Price Richard A., Turner J. Harvey, Phase I-II Study of Radiopeptide177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors, 10.1089/cbr.2012.1276
  45. Rashidi Armin, Sorscher Steven M., Temozolomide-associated myelodysplasia 6 years after treatment of a patient with pancreatic neuroendocrine tumor, 10.3109/10428194.2014.999327
  46. Brieau Bertrand, Hentic Olivia, Lebtahi Rachida, Palazzo Maxime, Ben Reguiga Makrem, Rebours Vinciane, Maire Frederique, Hammel Pascal, Ruszniewski Philippe, Fenaux Pierre, High risk of myelodysplastic syndrome and acute myeloid leukemia after177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy, 10.1530/erc-15-0543
  47. Bodei Lisa, Modlin Irvin M, Luster Markus, Forrer Flavio, Cremonesi Marta, Hicks Rodney J, Ezziddin Samer, Kidd Mark, Chiti Arturo, Myeloid neoplasms after chemotherapy and PRRT: myth and reality, 10.1530/erc-16-0258
  48. Kesavan Murali, Turner J. Harvey, Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience, 10.1089/cbr.2016.2035
  49. Garin E., Le Jeune F., Devillers A., Cuggia M., de Lajarte-Thirouard A.-S., Bouriel C., Boucher E., Raoul J.-L., Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors, 10.2967/jnumed.108.057505
  50. Bahri H., Laurence L., Edeline J., Leghzali H., Devillers A., Raoul J.-L., Cuggia M., Mesbah H., Clement B., Boucher E., Garin E., High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation, 10.2967/jnumed.114.144386
  51. Binderup T., Knigge U., Loft A., Federspiel B., Kjaer A., 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors, 10.1158/1078-0432.ccr-09-1759
  52. Hofman M. S., Michael M., Kashyap R., Hicks R. J., Modifying the Poor Prognosis Associated with 18F-FDG-Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT), 10.2967/jnumed.115.154500
  53. Perren Aurel, Couvelard Anne, Scoazec Jean-Yves, Costa Frederico, Borbath Ivan, Delle Fave Gianfranco, Gorbounova Vera, Gross David, Grossman Ashley, Jensen Robert T., Kulke Matthew, Oberg Kjell, Rindi Guido, Sorbye Halfdan, Welin Staffan, , ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification, 10.1159/000457956
  54. Sundin Anders, Arnold Rudolf, Baudin Eric, Cwikla Jaroslaw B., Eriksson Barbro, Fanti Stefano, Fazio Nicola, Giammarile Francesco, Hicks Rodney J., Kjaer Andreas, Krenning Eric, Kwekkeboom Dik, Lombard-Bohas Catherine, O'Connor Juan M., O'Toole Dermot, Rockall Andrea, Wiedenmann Bertram, Valle Juan W., Vullierme Marie-Pierre, , ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging, 10.1159/000471879
  55. Modlin Irvin M, Oberg Kjell, Chung Daniel C, Jensen Robert T, de Herder Wouter W, Thakker Rajesh V, Caplin Martyn, Delle Fave Gianfranco, Kaltsas Greg A, Krenning Eric P, Moss Steven F, Nilsson Ola, Rindi Guido, Salazar Ramon, Ruszniewski Philippe, Sundin Anders, Gastroenteropancreatic neuroendocrine tumours, 10.1016/s1470-2045(07)70410-2
  56. Oberg Kjell, Modlin Irvin M, De Herder Wouter, Pavel Marianne, Klimstra David, Frilling Andrea, Metz David C, Heaney Anthony, Kwekkeboom Dik, Strosberg Jonathan, Meyer Timothy, Moss Steven F, Washington Kay, Wolin Edward, Liu Eric, Goldenring James, Consensus on biomarkers for neuroendocrine tumour disease, 10.1016/s1470-2045(15)00186-2
  57. Hicks R.J., Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy, 10.1102/1470-7330.2010.9007
  58. Pattison David A., Hofman Michael S., Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies, 10.1016/j.cpet.2015.05.005
  59. Raj Nitya, Valentino Emily, Capanu Marinela, Tang Laura H., Basturk Olca, Untch Brian R., Allen Peter J., Klimstra David S., Reidy-Lagunes Diane, Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology : Well Differentiated Versus Poorly Differentiated, 10.1097/mpa.0000000000000735
  60. Tang Laura H., Basturk Olca, Sue Jillian J., Klimstra David S., A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas : , 10.1097/pas.0000000000000662
  61. Brunner Philippe, Jörg Ann-Catherine, Glatz Katharina, Bubendorf Lukas, Radojewski Piotr, Umlauft Maria, Marincek Nicolas, Spanjol Petar-Marko, Krause Thomas, Dumont Rebecca A., Maecke Helmut R., Müller-Brand Jan, Briel Matthias, Schmitt Anja, Perren Aurel, Walter Martin A., The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors, 10.1007/s00259-016-3486-2
  62. Rolleman Edgar J., Melis Marleen, Valkema Roelf, Boerman Otto C., Krenning Eric P., de Jong Marion, Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues, 10.1007/s00259-009-1282-y
  63. Jamar François, Barone Raffaella, Mathieu Isabelle, Walrand Stéphan, Labar Daniel, Carlier Pascal, Camps Joëlle, Schran Horst, Chen TianLing, Smith M. Charles, Bouterfa Hakim, Valkema Roelf, Krenning Eric P., Kvols Larry K., Pauwels Stanislas, 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion, 10.1007/s00259-003-1117-1
  64. Bushnell David, Menda Yusuf, O'Dorisio Thomas, Madsen Mark, Miller Sara, Carlisle Thomas, Squires Shayne, Kahn Daniel, Walkner Wayne, Connolly Mary, O'Dorisio Sue, Karwal Mark, Ponto James, Bouterfa Hakim, Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher™]) Treatment, 10.1089/108497804773391658
  65. Giovacchini Giampiero, Nicolas Guillaume, Freidank Heike, Mindt Thomas L., Forrer Flavio, Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy, 10.1007/s00259-011-1826-9
  66. Lhommel Renaud, Goffette Pierre, Van den Eynde Marc, Jamar François, Pauwels Stanislas, Bilbao Jose I., Walrand Stephan, Yttrium-90 TOF PET scan demonstrates high-resolution biodistribution after liver SIRT, 10.1007/s00259-009-1210-1
  67. Walrand S., Jamar F., van Elmbt L., Lhommel R., Bekonde E. B., Pauwels S., 4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90Y PET, 10.2967/jnumed.110.080093
  68. Helisch Andreas, F�rster GregorJ., Reber Helmut, Buchholz Hans-Georg, Arnold Rudolf, G�ke Burkhard, Weber MatthiasM., Wiedenmann Bertram, Pauwels Stanislas, Haus Ulrike, Bouterfa Hakim, Bartenstein Peter, Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours, 10.1007/s00259-004-1561-6
  69. Jackson Price A., Beauregard Jean-Mathieu, Hofman Michael S., Kron Tomas, Hogg Annette, Hicks Rodney J., An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging : Automated radionuclide voxelized dosimetry, 10.1118/1.4824318
  70. Beauregard Jean-Mathieu, Hofman Michael S., Pereira Jucilene M., Eu Peter, Hicks Rodney J., Quantitative 177 Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system, 10.1102/1470-7330.2011.0012
  71. Kwekkeboom Dik J., Teunissen Jaap J., Bakker Willem H., Kooij Peter P., de Herder Wouter W., Feelders Richard A., van Eijck Casper H., Esser Jan-Paul, Kam Boen L., Krenning Eric P., Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors, 10.1200/jco.2005.08.066
  72. Baum Richard P., Kulkarni Harshad R., Carreras Cecilia, Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine Neoplasms, 10.1053/j.semnuclmed.2012.01.002
  73. Kunikowska Jolanta, Królicki Leszek, Hubalewska-Dydejczyk Alicja, Mikołajczak Renata, Sowa-Staszczak Anna, Pawlak Dariusz, Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?, 10.1007/s00259-011-1833-x
  74. Kong Grace, Callahan Jason, Hofman Michael S., Pattison David A., Akhurst Tim, Michael Michael, Eu Peter, Hicks Rodney J., High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours, 10.1007/s00259-016-3527-x
  75. Knigge U., Capdevila J., Bartsch D.K., Baudin E., Falkerby J., Kianmanesh R., Kos-Kudla B., Niederle B., Nieveen van Dijkum E., O'Toole D., Pascher A., Reed N., Sundin A., Vullierme M.-P., , ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation, 10.1159/000458155
  76. Valkema Roelf, Pauwels Stanislas, Kvols Larry K., Barone Raffaella, Jamar Francois, Bakker Willem H., Kwekkeboom Dik J., Bouterfa Hakim, Krenning Eric P., Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors, 10.1053/j.semnuclmed.2006.01.001
  77. Pfeifer Andreas Klaus, Gregersen Tine, Grønbæk Henning, Hansen Carsten Palnæs, Müller-Brand Jan, Herskind Bruun Karin, Krogh Klaus, Kjær Andreas, Knigge Ulrich, Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in Switzerland, 10.1159/000324096
  78. Cwikla J. B., Sankowski A., Seklecka N., Buscombe J. R., Nasierowska-Guttmejer A., Jeziorski K. G., Mikolajczak R., Pawlak D., Stepien K., Walecki J., Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study, 10.1093/annonc/mdp372
  79. Swärd Christina, Bernhardt Peter, Ahlman Håkan, Wängberg Bo, Forssell-Aronsson Eva, Larsson Maria, Svensson Johanna, Rossi-Norrlund Rauni, Kölby Lars, [177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney, 10.1007/s00268-009-0387-6
  80. Garkavij Michael, Nickel Mattias, Sjögreen-Gleisner Katarina, Ljungberg Michael, Ohlsson Tomas, Wingårdh Karin, Strand Sven-Erik, Tennvall Jan, 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy, 10.1002/cncr.24796
  81. Bodei Lisa, Cremonesi Marta, Grana Chiara M., Fazio Nicola, Iodice Simona, Baio Silvia M., Bartolomei Mirco, Lombardo Dario, Ferrari Mahila E., Sansovini Maddalena, Chinol Marco, Paganelli Giovanni, Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study, 10.1007/s00259-011-1902-1
  82. Paganelli Giovanni, Sansovini Maddalena, Ambrosetti Alice, Severi Stefano, Monti Manuela, Scarpi Emanuela, Donati Caterina, Ianniello Annarita, Matteucci Federica, Amadori Dino, 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study, 10.1007/s00259-014-2735-5
  83. Kong Grace, Callahan Jason, Hofman Michael S., Pattison David A., Akhurst Tim, Michael Michael, Eu Peter, Hicks Rodney J., High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours, 10.1007/s00259-016-3527-x
Bibliographic reference Hicks, Rodney J ; Kwekkeboom, Dik J ; Krenning, Eric ; Bodei, Lisa ; Grozinsky-Glasberg, Simona ; et. al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.. In: Neuroendocrinology : international journal for basic and clinical studies on neuroendocrine relationships, Vol. 105, p. 295-309 (2017)
Permanent URL http://hdl.handle.net/2078.1/194900